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Summary
Background We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 
1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction 
regimen after primary surgery for early breast cancer. Here, we present 5-year results of the FAST-Forward trial.
Methods FAST-Forward is a multicentre, phase 3, randomised, non-inferiority trial done at 97 hospitals (47 radiotherapy 
centres and 50 referring hospitals) in the UK. Patients aged at least 18 years with invasive carcinoma of the breast 
(pT1–3, pN0–1, M0) after breast conservation surgery or mastectomy were eligible. We randomly allocated patients to 
either 40 Gy in 15 fractions (over 3 weeks), 27 Gy in five fractions (over 1 week), or 26 Gy in five fractions (over 1 week) 
to the whole breast or chest wall. Allocation was not masked because of the nature of the intervention. The primary 
endpoint was ipsilateral breast tumour relapse; assuming a 2% 5-year incidence for 40 Gy, non-inferiority was 
predefined as ≤1·6% excess for five-fraction schedules (critical hazard ratio [HR] of 1·81). Normal tissue effects were 
assessed by clinicians, patients, and from photographs. This trial is registered at isrctn.com, ISRCTN19906132.
Findings Between Nov 24, 2011, and June 19, 2014, we recruited and obtained consent from 4096 patients from 97 UK 
centres, of whom 1361 were assigned to the 40 Gy schedule, 1367 to the 27 Gy schedule, and 1368 to the 26 Gy 
schedule. At a median follow-up of 71·5 months (IQR 71·3 to 71·7), the primary endpoint event occurred in 79 patients 
(31 in the 40 Gy group, 27 in the 27 Gy group, and 21 in the 26 Gy group); HRs versus 40 Gy in 15 fractions were 0·86 
(95% CI 0·51 to 1·44) for 27 Gy in five fractions and 0·67 (0·38 to 1·16) for 26 Gy in five fractions. 5-year incidence of 
ipsilateral breast tumour relapse after 40 Gy was 2·1% (1·4 to 3·1); estimated absolute differences versus 40 Gy in 
15 fractions were –0·3% (–1·0 to 0·9) for 27 Gy in five fractions (probability of incorrectly accepting an inferior five-
fraction schedule: p=0·0022 vs 40 Gy in 15 fractions) and –0·7% (–1·3 to 0·3) for 26 Gy in five fractions (p=0·00019 vs 
40 Gy in 15 fractions). At 5 years, any moderate or marked clinician-assessed normal tissue effects in the breast or 
chest wall was reported for 98 of 986 (9·9%) 40 Gy patients, 155 (15·4%) of 1005 27 Gy patients, and 121 of 1020 (11·9%) 
26 Gy patients. Across all clinician assessments from 1–5 years, odds ratios versus 40 Gy in 15 fractions were 1·55 
(95% CI 1·32 to 1·83, p<0·0001) for 27 Gy in five fractions and 1·12 (0·94 to 1·34, p=0·20) for 26 Gy in five fractions. 
Patient and photographic assessments showed higher normal tissue effect risk for 27 Gy versus 40 Gy but not for 
26 Gy versus 40 Gy.
Interpretation 26 Gy in five fractions over 1 week is non-inferior to the standard of 40 Gy in 15 fractions over 3 weeks 
for local tumour control, and is as safe in terms of normal tissue effects up to 5 years for patients prescribed adjuvant 
local radiotherapy after primary surgery for early-stage breast cancer.
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Introduction
The Early Breast Cancer Trialists’ Collaborative Group 
systematic overview confirms that radiotherapy after 
primary surgery in women with early-stage cancers 
reduces locoregional cancer recurrence and breast cancer 
deaths, including patients with positive lymph nodes 
treated by mastectomy and axillary clearance.1,2 For many 
decades, schedules of adjuvant radiotherapy for these 
patients delivered 25 fractions of 2 Gy over 5 weeks. 
Randomised controlled trials with long-term follow-up 
have since confirmed that fewer, larger fractions giving a 
lower total dose are at least as safe and effective as the 
previously used international standard.3–10 Specifically, 
mature data confirm the safety and non-inferiority of 15 or 
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16 fractions of about 2·7 Gy to total doses of 40·0 Gy or 
42·5 Gy.5,8 A 3-week schedule of 15 fractions has been 
the UK standard of care for adjuvant locoregional radio-
therapy for early breast cancer since 2009 and is now an 
international standard for adjuvant local radiotherapy.11,12 
There is no reason to assume that 15 fractions represent 
the lower limits of this hypofractionated and accelerated 
approach. We report outcomes of the FAST-Forward 
randomised phase 3 trial testing two dose levels of a five-
fraction regimen delivered in 1 week against 40 Gy in 
15 fractions over 3 weeks for patients prescribed local 
radiotherapy after breast conservation surgery or 
mastectomy for early breast cancer. The objectives are to 
identify a 1-week schedule non-inferior to a standard 
3-week regimen for 5-year local tumour control and 
similar in terms of late adverse effects. FAST-Forward was 
informed by the FAST trial that tested two dose levels of 
five once-weekly fractions;13,14 FAST trial results to 10-year 
follow-up are to be published soon. The trial design used 
dose levels estimated to be the upper and lower bounds 
that are isoeffective with the control schedule in terms of 
tumour control and normal tissue effects.
Methods
Study design
FAST-Forward is a multicentre, non-blinded, phase 3, 
randomised, non-inferiority trial, done at 97 hospitals 
(47 radiotherapy centres and 50 referring hospitals) in 
the UK, testing the safety and efficacy of five-fraction 
schedules of adjuvant radiotherapy to the whole breast 
or chest wall delivered in 1 week compared with the UK 
standard 15-fraction 3-week schedule. Substudies 
included a published acute toxicity study,15 photo -
graphic assess ments of late adverse effects, and patient-
reported outcomes; not all centres participated in the 
substudies. Following recruitment into the main trial a 
further substudy opened, testing the same fractionation 
schedules for patients requiring radiotherapy to the 
axilla or supraclavicular fossa lymph nodes after sentinel 
node biopsy or supraclavicular fossa only (levels 3–4) 
after axillary dissection with a primary endpoint 
focusing on safety. Patients and results from this 
substudy are not reported here because follow-up is not 
yet mature. FAST-Forward was approved by the national 
South East Coast Kent research ethics committee 
(11/LO/0958) and local research and development 
offices of all participating centres. The trial protocol is 
in the appendix (pp 15–78).
Patients
Eligible patients were women or men aged at least 18 years 
with invasive carcinoma of the breast (pT1–3, pN0–1, M0) 
following complete microscopic excision of the primary 
tumour by breast conservation surgery or mastectomy 
(reconstruction allowed), recruited in the UK from 
47 radiotherapy centres and 50 referral centres. A protocol 
amendment on Feb 15, 2013, excluded the lowest-risk 
patients (aged ≥65 years, pT1, grade 1 or 2, oestrogen 
Research in context
Evidence before this study
We searched PubMed on April 22, 2020, using the search terms 
“breast cancer”, “adjuvant radiotherapy”, “hypofractionation”, 
and “randomised clinical trials”. We searched for primary 
research and reviews published in English between Jan 1, 1980, 
and April 22, 2020. We found 13 randomised studies testing 
adjuvant breast hypofractionated radiotherapy regimens 
against standard fractionation ranging in sample size from 30 to 
2236 patients. All offered consistent support for the 
experimental approach.
Radiotherapy (radiation therapy) after primary surgery for early 
breast cancer has historically been delivered in five daily doses 
(fractions) of 1·8–2·0 Gy per week over at least 5 weeks, 
but randomised phase 3 clinical trials done in Canada, the UK, 
and subsequently, China and Denmark have confirmed the 
safety and efficacy of 15-fraction or 16-fraction schedules using 
daily fractions of 2·7 Gy. Four of these trials published 10-year 
follow-up data on a total of 7000 patients, and 3-week 
schedules have replaced traditional regimens in many countries 
over the past decade for most, if not all, patients prescribed 
local or locoregional radiation therapy after breast conservation 
surgery or mastectomy. Most recently, long-term outcome data 
for a five-fraction schedule delivered by once-weekly 
treatments has been reported, which suggests further scope for 
simplifying curative radiotherapy for women with early breast 
cancer.
Added value of this study
15 or 16 fractions over 3·0–3·2 weeks are unlikely to represent 
the limits of this approach, called hypofractionation. 
The FAST-Forward trial shows that 26 Gy in five fractions of 
5·2 Gy to the conserved breast or post-mastectomy chest wall 
after primary surgery is non-inferior in terms of 5-year 
ipsilateral local tumour relapse to 40 Gy in 15 fractions over 
3 weeks within an absolute 1·6% non-inferiority margin 
compared with 2% incidence with 40 Gy. The 5-day schedule 
causes milder early skin reaction and similar rates of late 
adverse effects. When mature, a randomised FAST-Forward 
substudy will report the safety of the five-fraction regimen for 
patients prescribed radiotherapy to breast or chest wall 
combined with axilla or supraclavicular fossa.
Implications of all the available evidence
FAST-Forward results confirm that 26 Gy in five fractions is as 
effective and safe as an international standard 15-fraction 
regimen after primary surgery for early breast cancer. 
The 1-week schedule has major benefits over the 3-week or 
5-week regimens in terms of convenience and cost for patients 
and for health services globally.
See Online for appendix
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receptor [ER] positive, HER2 negative, pN0, M0) to 
increase the overall primary event rate. All patients 
had axillary surgery (sentinel node biopsy or axillary 
dissection); nodal radiotherapy was not allowed in the 
main study. Concurrent endocrine therapy or trastu-
zumab, or both, were permitted but not concurrent 
chemotherapy. For the patient-reported outcomes sub-
study all patients at participating centres were eligible. 
All patients who had breast conservation surgery were 
eligible for the photographic substudy at participating 
centres. A small number of patients who had had 
mastectomy were recruited into the photographic 
substudy to validate the scoring method in patients who 
had chest wall radiotherapy, but are not reported here 
because photographs were only available for 76 patients. 
All patients provided written informed consent.
Randomisation and masking
Patients were randomly assigned (1:1:1) to receive either 
40 Gy in 15 fractions of 2·67 Gy; 27 Gy in five fractions of 
5·4 Gy; or 26 Gy in five fractions of 5·2 Gy. A sequential 
tumour bed radiotherapy boost to the conserved breast 
was allowed, with centres required to specify boost 
intention and dose (10 Gy or 16 Gy in 2-Gy fractions) 
before randomisation. Randomisation was done by 
telephone or fax from the recruiting centre to the 
Institute of Cancer Research-Clinical Trials and Statistics 
Unit (ICR-CTSU), Sutton, London, UK, and used an in-
house bespoke trial-specific randomisation system set-
up by the ICR-CTSU IT team. Computer-generated 
random permuted blocks were used (block sizes 6 and 
9), stratified by radiotherapy centre and risk group (high 
[age <50 years or grade 3] vs low [age ≥50 years and 
grade 1 or 2]). Treatment allocation was not masked to 
clinicians or patients.
Test dose levels were informed by START8 and FAST15 
trials generating α/β values for late normal tissue effects. 
Assuming an α/β value of 3 Gy and no effect of overall 
time on outcomes, 27 Gy in five fractions of 5·4 Gy was 
predicted to match late normal tissue effects of 40 Gy in 
15 fractions of 2·7 Gy or 46 Gy in 23 fractions of 2 Gy. 
Allowance for a possible effect of treatment time informed 
the choice of the slightly lower 26 Gy dose level.
Radiotherapy
The whole breast clinical target volume, including the 
soft tissues from 5 mm below the skin surface to the deep 
fascia, was either established from field-based tangential 
fields or the volume was contoured prospectively. Post-
mastectomy chest wall clinical target volume encom-
passed post-surgical skin flaps and underlying soft tissues 
to the deep fascia; both excluded underlying muscle and 
rib cage. Surgeons were strongly encouraged to mark the 
tumour cavity walls with titanium clips or gold seeds at 
the time of breast conservation surgery in order to aid 
placement of tangential fields and delineation of tumour 
bed. A typical margin of 10 mm was added around the 
breast or chest wall clinical target volume accounting for 
set-up error, breast swelling, and breathing to create a 
planning target volume (PTV). For all patients, a full 
3D CT set of outlines covering the whole breast and 
organs at risk was collected with a slice separation up to 
5 mm, and organs at risk were outlined prospectively. A 
tangential opposing pair beam arrangement encompassed 
the whole breast or chest wall PTV, minimising the 
ipsilateral lung and heart exposure. The treatment plan 
was optimised with 3D dose compensation to achieve the 
Figure 1: FAST-Forward trial profile
*One patient had no radiotherapy as they were unable to get into a stable position; three were given 40 Gy in 
15 fractions (one because of concern for brachial plexus, one decided on a different treatment plan, and one 
because of constraints of treatment planning). †One patient had no radiotherapy because they were diagnosed 
with pemphigoid and eight were given 40 Gy in 15 fractions (one because dose constraints were not met, one was 
unable to plan within protocol constraints because of tumour bed position, one had poor planning target volume 
coverage, one had technical difficulties in planning, one was transferred to direct electron field, one had a simulator 
plan because 3D images were not possible, one had a small pericardial effusion found at planning, and one gave no 
reason).
4110 patients enrolled and 
randomly assigned 
1370 patients allocated to 
27 Gy in five fractions 
(1 week) 
12 did not receive
allocated therapy
2 ineligible 
4 patient choice 
4 investigator 
decision*
1 withdrawal of 
consent
1 incorrect dose 
given
 
3 withdrew consent
for use of their data
1367 included in the 
intention-to-treat 
population
 
1355 patients received 
allocated therapy 
(per-protocol population) 
1231 patients with 5-year visit
form available
136 with no 5-year visit
form available
 93 died
 3 withdrew
 0 lost to 
follow-up
 40 forms not 
received
1372 patients allocated to 
26 Gy in five fractions 
(1 week) 
21 did not receive
allocated therapy
4 ineligible
6 patient choice 
9 investigator 
decision† 
2 treatment stopped 
early
4 withdrew consent 
for use of their data
1368 included in the 
intention-to-treat 
population
 
1347 patients received 
allocated therapy 
(per-protocol population) 
1232 patients with 5-year visit
form available
136 with no 5-year visit
form available
 75 died
 4 withdrew
 0 lost to follow-up
 57 forms not 
received
1368 patients allocated to 
40 Gy in 15 fractions 
(3 weeks) 
7 withdrew consent 
for use of their data
1361 included in the 
intention-to-treat 
population
 
7 did not receive 
allocated therapy
2 patient choice 
2 treatment 
prolonged 
because of patient 
illness
3 treatment stopped 
early 
 
1354 patients received 
allocated therapy 
(per-protocol population) 
1218 patients with 5-year visit
form available
143 with no 5-year visit
form available
72 died
15 withdrew
1 lost to
follow-up
55 forms not 
received
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following PTV dose distribution: more than 95% of PTV 
received 95% of prescribed dose, less than 5% of PTV 
received 105% or more, less than 2% of PTV received 
107% or more, and a global maximum of less than 110%. 
Dose constraints for the control group were as follows: 
volume of ipsilateral lung receiving 12 Gy less than 15%, 
and volume of heart receiving 2 Gy less than 30% and 
that receiving 10 Gy less than 5%. Dose constraints for 
the five-fraction schedules were as follows: volume of 
ipsilateral lung receiving 8 Gy less than 15%, and volume 
of heart receiving 1·5 Gy less than 30% and that receiving 
7 Gy less than 5%. X-ray beam energies for treatment 
were 6 MV or 10 MV, but a mixture of energies—eg, 6 MV 
and 10–15 MV—was allowed for larger patients, assessed 
on a case-by-case basis. Tumour bed boost was delivered 
via electrons or photons. Verification was done using 
electronic portal imaging using MV or kV x-rays. Control 
group treatment verification was required for at least 
three fractions in the first week with correction for any 
systematic error and then once weekly with a tolerance of 
5 mm. The five-fraction schedules required verification 
imaging for each fraction with recommendations to 
correct all measured displacements. A comprehensive 
quality assurance programme involved every radiotherapy 
centre before trial activation and continued throughout 
trial accrual; this was coordinated by the UK Radiotherapy 
Trials Quality Assurance team based at Mount Vernon 
Hospital, Northwood, UK. The radiotherapy planning 
pack is in the appendix (pp 79–103).
Assessments
Patients were assessed by clinicians for ipsilateral breast 
tumour relapse and late normal tissue effects at annual 
follow-up visits. Starting 12 months after trial entry, 
late-onset normal tissue effects in ipsilateral breast or 
chest wall (breast distortion, shrinkage, induration and 
telangiectasia; and breast or chest wall oedema and 
discomfort) were graded by clinicians on a four-point 
scale (none, a little, quite a bit, or very much), interpreted 
as none, mild, moderate, or marked. Symptomatic rib 
fracture, symptomatic lung fibrosis, and ischaemic 
heart disease were recorded. Clinical assessments of 
acute skin toxicity have been previously reported.15
In the patient-reported outcomes substudy, ques-
tionnaires were administered at baseline (before ran-
domisation) and at 3, 6, 12, 24, and 60 months, including 
the European Organisation for Research and Treatment 
of Cancer QLQ-BR23 breast cancer module, body image 
scale, and protocol-specific questions relating to changes 
to the affected breast after treatment (including breast 
appearance changed, smaller, harder or firmer, and skin 
appearance changed). Patient assess ments used a four-
point scale (not at all, a little, quite a bit, and very much).
In the photographic substudy, photographs were taken 
at baseline and at 2 and 5 years after radiotherapy. 
Change in photographic breast appearance compared 
with baseline (after surgery and before radiotherapy) was 
40 Gy in 
15 fractions 
(n=1361)
27 Gy in 
five fractions 
(n=1367)
26 Gy in 
five fractions 
(n=1368)
Age, years
Median (IQR) 60 (53–66) 61 (53–67) 61 (52–66)
Range 29–89 25–90 25–89
<40 12 (0·9%) 16 (1·2%) 28 (2·0%)
40–49 186 (13·7%) 173 (12·7%) 189 (13·8%)
50–59 440 (32·3%) 423 (30·9%) 414 (30·3%)
60–69 506 (37·2%) 511 (37·4%) 524 (38·3%)
70–79 175 (12·9%) 197 (14·4%) 172 (12·6%)
≥80 42 (3·1%) 47 (3·4%) 41 (3·0%)
Sex
Female 1355 (99·6%) 1365 (99·9%) 1362 (99·6%)
Male 6 (0·4%) 2 (0·1%) 4 (0·3%)
Unknown 0 0 2 (0·1%)
Tumour grade
1 315 (23·1%) 315 (23·0%) 300 (21·9%)
2 660 (48·5%) 663 (48·5%) 690 (50·4%)
3 386 (28·4%) 389 (28·5%) 378 (27·6%)
Risk group
Low (age ≥50 and grade 1 or 2) 843 (61·9%) 854 (62·5%) 854 (62·4%)
High (age <50 or grade 3, or both) 518 (38·1%) 513 (37·5%) 514 (37·6%)
Primary surgery
Breast conservation surgery 1270 (93·3%) 1278 (93·5%) 1284 (93·9%)
Breast conservation surgery with 
oncoplastic technique
42 (3·1%) 33 (2·4%) 42 (3·1%)
Mastectomy 91 (6·7%) 89 (6·5%) 84 (6·1%)
Mastectomy with immediate 
reconstruction
8 (0·6%) 11 (0·8%) 7 (0·5%)
Autologous reconstruction 5/8 (62·5%) 7/11 (63·6%) 3/7 (42·9%)
Implant-based reconstruction 2/8 (25·0%) 4/11 (27·3%) 4/7 (57·1%)
Reconstruction type not specified 1/8 (12·5%) 0 0
Side of primary tumour
Left 726 (53·3%) 674 (49·3%) 662 (48·4%)
Right 635 (46·7%) 693 (50·7%) 704 (51·5%)
Unknown 0 0 2 (0·1%)
Maximal extent of axillary staging
Sentinel node biopsy or guided 
axillary sampling
1157 (85·0%) 1184 (86·6%) 1164 (85·1%)
Axillary clearance 200 (14·7%) 181 (13·2%) 201 (14·7%)
Other 4 (0·3%) 2 (0·1%) 1 (0·1%)
Unknown 0 0 2 (0·1%)
Pathological node status
Positive 257 (18·9%) 243 (17·8%) 256 (18·7%)
Negative 1103 (81·0%) 1124 (82·2%) 1110 (81·1%)
Unknown 1 (0·1%) 0 2 (0·1%)
Histological type
Infiltrating ductal 1084 (79·6%) 1096 (80·2%) 1086 (79·4%)
Lobular 144 (10·6%) 139 (10·2%) 127 (9·3%)
Mixed 51 (3·7%) 63 (4·6%) 65 (4·8%)
Other 82 (6·0%) 69 (5·0%) 87 (6·4%)
Unknown 0 0 3 (0·2%)
Pathological tumour size, cm
Median (IQR) 1·6 (1·1–2·2) 1·6 (1–2·2) 1·6 (1·1–2·4)
(Table 1 continues on next page)
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scored on a three-point scale (none, mild, or marked) 
based on changes in breast size and shape relative to the 
contralateral breast. Patients were ineligible for further 
photographic assessments after breast reconstruction 
surgery and further ipsilateral disease. Digital photo-
graphs were scored by three observers who were masked 
to patient identity and treatment allocation, following 
scoring procedures established in the START trials.16 
Breast size and surgical deficit were assessed from the 
baseline photographs on a three-point scale (small, 
medium, and large).
Outcomes
The primary endpoint was ipsilateral breast tumour 
relapse, defined as invasive carcinoma or ductal carci-
noma in situ presenting anywhere in the ipsilateral 
breast parenchyma or overlying skin or post-mastectomy 
chest wall, whether considered local recurrence or new 
primary tumour. Data on first regional relapse (axilla, 
supraclavicular fossa, and internal mammary chain), 
distant metastases, new primary cancer, and death were 
collected. Key secondary endpoints were late normal 
tissue effects assessed by clinicians, patients, and from 
photographs, and other disease-related and survival 
outcomes (locoregional relapse, distant relapse, disease-
free survival, and overall survival; appendix p 29).
Statistical analysis
The target sample size was 4000 patients (balanced 
allocation between groups). This provided 80% power 
(one-sided α of 0·025 allowing for non-inferiority 
hypothesis and a simple Bonferroni correction taking into 
account comparisons between each test schedule and the 
control group17) to exclude an absolute increase of 1·6% in 
5-year ipsilateral breast tumour relapse incidence for a 
five-fraction schedule compared with control, assuming 
2% 5-year incidence in the 40 Gy group (START data,7 and 
allowing for reduced ipsilateral breast tumour relapse due 
to evolution of surgical techniques and systemic therapy). 
The 1·6% absolute non-inferiority margin was defined at 
the trial design stage by the protocol development group, 
which included clinicians and patient advocates and was 
considered to be acceptable and appropriate. Binary 
proportions were used for the sample size calculations 
because event rates are so low. Estimates allowed for 
10% loss to follow-up or unevaluable patients, expected to 
be largely due to development of metastatic disease. 
2196 patients (732 per group) was estimated for the 
photographic and patient-reported outcomes substudies 
to provide 80% power to detect an 8% difference in the 
5-year prevalence of late normal tissue effects between the 
five-fraction schedules (assuming 35% with 5-year mild 
or marked change in photographic breast appear ance 
from START-B 40 Gy results7), allowing for 10% loss to 
follow-up or unevaluable patients.
Kaplan-Meier estimates (with 95% CIs) of 5-year 
ipsilateral breast tumour relapse incidence were 
40 Gy in 
15 fractions 
(n=1361)
27 Gy in 
five fractions 
(n=1367)
26 Gy in 
five fractions 
(n=1368)
(Continued from previous page)
Pathological T stage
T1mi 4 (0·3%) 5 (0·4%) 6 (0·4%)
T1a 69 (5·1%) 68 (5·0%) 51 (3·7%)
T1b 258 (19·0%) 270 (19·8%) 256 (18·7%)
T1c 612 (45·0%) 601 (44·0%) 602 (44·0%)
T2 394 (28·9%) 389 (28·5%) 424 (31·0%)
T3 21 (1·5%) 30 (2·2%) 25 (1·8%)
Unknown 3 (0·2%) 4 (0·3%) 4 (0·3%)
ER and HER2 status
ER  positive HER2 positive 103 (7·6%) 103 (7·5%) 93 (6·8%)
ER positive HER2 negative 1108 (81·4%) 1130 (82·7%) 1097 (80·2%)
ER negative HER2 positive 32 (2·4%) 34 (2·5%) 42 (3·1%)
ER negative HER2 negative 111 (8·2%) 96 (7·0%) 128 (9·4%)
Not known 7 (0·5%) 4 (0·3%) 8 (0·6%)
Progesterone receptor status
Positive 577 (73·1%)† 541 (70·3%)† 566 (69·8%)†
Negative 212 (26·9%)† 229 (29·7%)† 245 (30·2%)†
Not done 571 (42·0%) 596 (43·6%) 555 (40·6%)
Missing on form 1 (0·1%) 1 (0·1%) 2 (0·1%)
Lymphovascular invasion
Present 186 (13·7%) 178 (13·0%) 202 (14·8%)
Absent 1085 (79·7%) 1084 (79·3%) 1055 (77·1%)
Uncertain 34 (2·5%) 40 (2·9%) 51 (3·7%)
Unknown 56 (4·1%) 65 (4·8%) 60 (4·4%)
Neoadjuvant chemotherapy received‡
Yes 48 (3·5%) 56 (4·1%) 43 (3·1%)
No 1312 (96·4%) 1311 (95·9%) 1323 (96·7%)
Unknown 1 (0·1%) 0 2 (0·1%)
Adjuvant therapy received: all patients
Chemotherapy§ 333/1360 (24·5%) 324/1367 (23·7%) 370/1366 (27·1%)
Adjuvant therapy received:‡ HER2-positive patients
Chemotherapy and trastuzumab 84/135 (62·2%) 85/137 (62·0%) 100/135 (74·1%)
Trastuzumab, no chemotherapy 16/135 (11·9%) 13/137 (9·5%) 13/135 (9·6%)
Chemotherapy, no trastuzumab 2/135 (1·5%) 2/137 (1·5%) 0
No chemotherapy, no trastuzumab 33/135 (24·4%) 37/137 (27·0%) 22/135 (16·3%)
Adjuvant therapy received:‡ ER-positive patients
Endocrine therapy 1169/1216 (96·1%) 1186/1237 (95·9%) 1157/1196 (96·7%)
Boost given
Yes 342 (25·1%) 337 (24·7%) 332 (24·3%)
No 1017 (74·7%) 1027 (75·1%) 1031 (75·4%)
Not known 2 (0·1%) 3 (0·2%) 5 (0·4%)
Boost dose
10 Gy in five fractions 260/342 (76·0%) 273/337 (81·0%) 257/332 (77·4%)
16 Gy in eight fractions 80/342 (23·4%) 64/337 (19·0%) 75/332 (22·6%)
Unknown 2/342 (0·6%) 0 0
Data are n (%) or n/N (%) unless otherwise stated. ER=oestrogen receptor. *14 patients withdrew consent for any of 
their data to be used in analysis. †These percentages are calculated out of total patients who had available results for 
this test. ‡Patients could have more than one type of adjuvant systemic therapy. §Chemotherapy type (for those 
specified): anthracyclines (n=584), taxane and anthracyclines (n=348), taxane and other—eg, docetaxel, carboplatin, 
and trastuzumab (n=83), and other (n=3).
Table 1: Demographic, clinical, and treatment characteristics at randomisation (n=4096)*
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calculated, and hazard ratios (HRs; with 95% CIs) 
comparing fractionation schedules obtained from Cox 
proportional hazards regression, censoring patients at 
date of death or last follow-up. Absolute differences (with 
95% CIs) in 5-year ipsilateral breast tumour relapse 
incidence were estimated by applying the HRs (and 
95% CIs) to the control group 5-year event-free estimate.18 
Primary assessment of non-inferiority was based on 
whether the upper limit of the two-sided 95% CI 
(corresponding to one-sided 97·5% CI) for the absolute 
difference in 5-year ipsilateral breast tumour relapse was 
less than 1·6%. Non-inferiority of each five-fraction 
schedule versus control was also tested using the a priori 
critical HR of 1·81 (ln0·964/ln0·98, from protocol-
specified incidence); p<0·025 was deemed statistically 
signifi cant (probability of incorrectly accepting an infer-
ior five-fraction schedule). An exploratory competing 
risks analysis was done for ipsilateral breast tumour 
relapse, with death from any cause as a competing event 
in a Fine–Gray competing risks regression model.
Clinician and patient assessments of late normal tissue 
effects were analysed as follows: (1) 5-year cross-sectional 
analyses compared prevalence of moderate or marked 
effects versus none or mild effects between groups using 
risk ratios and risk differences and Fisher’s exact test; and 
(2) longitudinal analyses of moderate or marked effects 
(vs none or mild) using generalised estimating equations19 
including all assessments, comparing groups across the 
whole follow-up period using odds ratios (ORs) and the 
Wald test. Generalised estimating equations models 
included a term for years of follow-up, enabling time 
trends to be modelled. Additionally, to enable comparison 
of clinician-assessed normal tissue effects with results 
reported from other trials, survival analysis methods 
analysed time to first moderate or marked event, including 
Kaplan-Meier estimates of cumulative incidence, and 
groups compared using HRs from Cox proportional 
hazards regression and the pairwise log-rank test.
Scores for change in photographic breast appearance at 
2 and 5 years were modelled using generalised estimating 
equations. Categories of mild and marked change in 
photographic breast appearance were combined for 
analysis because very few had marked changes. Pairwise 
comparisons of mild or marked change at 2 or 5 years 
between groups were described by ORs obtained from 
the generalised estimating equations models and the 
Wald test. Because of multiple testing, a significance 
level of 0·005 was used for the clinician and patient 
normal tissue effects assessments; all hypotheses for the 
normal tissue effects endpoints were two-sided.
Estimates of fractionation sensitivity (α/β values) in 
FAST-Forward were obtained for the primary endpoint of 
ipsilateral breast tumour relapse and late normal tissue 
effects as per methods in the START and FAST trials.3 
The α/β estimate for breast cancer was obtained from a 
Cox proportional hazards regression model of time to 
first ipsilateral breast tumour relapse, and for late normal 
tissue effects from generalised estimating equations 
models including all follow-up assessments (separate 
models for photographic and clinician assessments). 
Each model included terms for total dose and total dose 
multiplied by fraction size; the α/β ratio was calculated by 
dividing the two parameter estimates respectively, with a 
95% CI estimated from the model using the covariance of 
the two estimates (lower confidence limits were truncated 
at zero). Isoeffect doses in 2 Gy equivalents (EQD2) were 
calculated for the five-fraction schedules, together with an 
estimate of the five-fraction schedule that would be 
isoeffective with 40 Gy in 15 fractions in terms of local 
tumour control and late normal tissue effects. No 
correction was made for difference in treatment time.
No formal interim analyses were done; accumulating 
data were monitored annually by the independent data 
monitoring committee. All analyses were performed on 
an intention-to-treat basis that included all patients 
Cumulative 
number of 
events
Estimated 
cumulative 
incidence by 
5 years (95% CI)
Hazard ratio (95% CI); 
p value
Estimated absolute 
difference vs 40 Gy 
at 5 years (95% CI)
Ipsilateral breast tumour (local) relapse*
40 Gy (n=1361) 31 (2·3%) 2·1% (1·4 to 3·1) 1 (ref) ··
27 Gy (n=1367) 27 (2·0%) 1·7% (1·2 to 2·6) 0·86 (0·51 to 1·44); 
0·56
–0·3% (–1·0 to 0·9)
26 Gy (n=1368) 21 (1·5%) 1·4% (0·9 to 2·2) 0·67 (0·38 to 1·16); 
0·15
–0·7% (–1·3 to 0·3)
Locoregional relapse†
40 Gy (n=1361) 43 (3·2%) 2·8% (2·0 to 3·9) 1 (ref) ··
27 Gy (n=1367) 35 (2·6%) 2·3% (1·6 to 3·3) 0·80 (0·51 to 1·25); 
0·33
–0·5% (–1·4 to 0·7)
26 Gy (n=1368) 29 (2·1%) 1·8% (1·2 to 2·7) 0·66 (0·41 to 1·06); 
0·083
–0·9% (–1·6 to 0·2)
Distant relapse
40 Gy (n=1361) 59 (4·3%) 3·8% (2·9 to 5·0) 1 (ref) ··
27 Gy (n=1367) 69 (5·0%) 4·7% (3·7 to 6·0) 1·16 (0·82 to 1·64); 
0·41
0·6% (–0·7 to 2·3)
26 Gy (n=1368) 76 (5·6%) 5·1% (4·0 to 6·4) 1·27 (0·90 to 1·79); 
0·17
1·0% (–0·4 to 2·9)
Any breast cancer-related event‡
40 Gy (n=1361) 119 (8·7%) 7·8% (6·5 to 9·4) 1 (ref) ··
27 Gy (n=1367) 112 (8·2%) 7·2% (5·9 to 8·7) 0·93 (0·71 to 1·20); 
0·56
–0·6% (–2·2 to 1·5)
26 Gy (n=1368) 114 (8·3%) 7·5% (6·2 to 9·0) 0·94 (0·73 to 1·22); 
0·65
–0·4% (–2·1 to 1·6)
All-cause mortality
40 Gy (n=1361) 92 (6·8%) 5·4% (4·3 to 6·8) 1 (ref) ··
27 Gy (n=1367) 105 (7·7%) 6·9% (5·7 to 8·4) 1·12 (0·85 to 1·48); 
0·42
0·6% (–0·8 to 2·5)
26 Gy (n=1368) 90 (6·6%) 5·6% (4·5 to 7·0) 0·96 (0·72 to 1·28); 
0·78
–0·2% (–1·5 to 1·5)
Hazard ratios less than 1 favour five-fraction schedules. p values were calculated by log-rank test (two-sided). *Includes 
three patients with angiosarcoma in ipsilateral breast (one in the 40 Gy group and two in the 26 Gy group). †Defined 
as ipsilateral breast tumour relapse or regional relapse (axilla, supraclavicular fossa, and internal mammary chain). 
‡Includes local, regional, or distant relapse, breast cancer death, or contralateral breast cancer (disease-free survival).
Table 2: Relapse and mortality by fractionation schedule: time-to-event analysis (n=4096)
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according to their allocated treatment regardless of what 
was actually received. Because the main hypothesis was 
non-inferiority, the primary endpoint was also tested in 
the per-protocol population, which excluded patients for 
whom a major deviation was reported. The database 
snapshot was taken on Nov 22, 2019; Stata, version 15 
(StataCorp), was used for analyses. The trial is registered 
at isrctn.com, ISRCTN19906132.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between Nov 24, 2011, and June 19, 2014, 4110 patients 
were enrolled in the FAST-Forward trial. After ran-
domisation, 14 patients withdrew consent for use of 
data and were removed from the intention-to-treat popula-
tion; thus, 4096 patients were included in the intention-
to-treat anlaysis (1361 assigned to 40 Gy in 15 fractions; 
1367 assigned to 27 Gy in five frac tions; and 1368 assigned 
to 26 Gy in five fractions; figure 1). Seven patients in the 
40 Gy group, 12 in the 27 Gy group, and 21 in the 26 Gy 
group did not receive the allocated therapy and were not 
included in the per-protocol popu lation. Compliance with 
allocated treatment was 99%. Demographic and clinical 
charac teristics at baseline were well balanced between 
groups (table 1). 5-year visit forms were available for 
3681 (96%) patients of 3833 still in follow-up (not died, 
withdrawn, or lost).
After a median follow-up of 71·5 months (IQR 71·3 to 
71·7), ipsilateral breast tumour relapse was recorded in 
79 patients (31 in the 40 Gy group, 27 in the 27 Gy group, 
and 21 in the 26 Gy group); HRs versus 40 Gy in 
15 fractions were 0·86 (95% CI 0·51 to 1·44) for 27 Gy in 
five fractions and 0·67 (0·38 to 1·16) for 26 Gy in five 
fractions. Estimated cumulative incidence of ipsilateral 
breast tumour relapse up to 5 years was 2·1% (95% CI 
1·4 to 3·1) for 40 Gy (expected incidence 2%), 1·7% 
(1·2 to 2·6) for 27 Gy and 1·4% (0·9 to 2·2) for 26 Gy 
(table 2, figure 2). Estimated absolute differences in 
ipsilateral breast tumour relapse versus 40 Gy were –0·3% 
(–1·0 to 0·9) for 27 Gy and –0·7% (–1·3 to 0·3) for 26 Gy. 
The upper confidence limits excluded an increase in 
ipsilateral breast tumour relapse of 1·6% or more so non-
inferiority can be claimed for both five-fraction schedules 
compared with 40 Gy in 15 fractions. A test against the 
Figure 2: Cumulative risk of ipsilateral breast tumour relapse by fractionation schedule
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27 Gy vs 40 Gy: hazard ratio 0·86 (95% CI 0·51 to 1·44); 
5-year difference –0·3% (95% CI –1·0 to 0·9); non-inferiority p=0·0022
26 Gy vs 40 Gy: hazard ratio 0·67 (95% CI 0·38 to 1·16); 
5-year difference –0·7% (95% CI –1·3 to 0·3); non-inferiority p=0·00019
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critical HR greater than 1·81 confirmed the result, with a 
p value of 0·0022 for 27 Gy and 0·00019 for 26 Gy 
compared with 40 Gy. Analyses in the per-protocol 
population were consistent (estimated absolute difference 
vs 40 Gy –0·4% [–1·0 to 0·8], p=0·0017 for 27 Gy and 
–0·6% [–1·2 to 0·4], p=0·00037 for 26 Gy; full data 
for per-protocol analyses not shown because treatment 
compliance was 99%). Comparing the five-fraction 
schedules, the estimated absolute difference in ipsilateral 
breast tumour relapse cumulative incidence up to 5 years 
was –0·4% (–1·0 to 0·6) for 26 Gy versus 27 Gy. The 
unadjusted α/β estimate for ipsilateral breast tumour 
relapse was 3·7 Gy (0·3 to 7·1), with EQD2 estimates of 
44·7 Gy for 40 Gy, 43·1 Gy for 27 Gy, and 40·6 Gy for 26 Gy 
with no correction for treatment time. Adjusting for risk 
group and ER and HER2 status made minimal difference 
(adjusted α/β estimate 3·7 Gy [95% CI 0·4 to 6·9]). HRs 
obtained from a competing risks analysis of ipsilateral 
breast tumour relapse with death from any cause as a 
competing event were almost identical to those from the 
primary analysis (HRs from competing risks model were 
0·85 [95% CI 0·51 to 1·43] for 27 Gy vs 40 Gy; and 0·67 
[0·38 to 1·16] for 26 Gy vs 40 Gy).
Regional relapses occurred in 34 (0·8%) of 4096 patients 
(13 [1·0%] of 1361 in the 40 Gy group, 11 [0·8%] in the 
27 Gy group, and ten [0·7%] in the 26 Gy group; 
table 3), six of which were concurrent with ipsilateral 
breast tumour relapse. Incidence of locoregional relapse, 
distant relapse, dis ease-free survival, and overall survival 
were similar between groups, with no statistically 
significant differences (table 2; appendix pp 3–4). No 
formal subgroup analyses were done because of the low 
number of primary endpoint events, but frequencies of 
ipsilateral breast tumour relapse, regional relapse, and 
distant relapse were tabulated according to age, grade, 
and ER and HER2 status for descriptive purposes; as 
expected, ipsilateral breast tumour relapse occurred in 
more of the patients with higher-grade primary tumours 
(appendix p 7). Invasive contralateral breast cancer 
was reported for 55 (1·3%) of 4096 patients (18 [1·3%] in 
the 40 Gy group, 17 [1·2%] in the 27 Gy group, and 
20 [1·5%] in the 26 Gy group; table 3), and non-breast 
second primary cancers were reported for 123 (3·0%) of 
4096 patients (42 [3·1%] in the 40 Gy group, 37 [2·7%] in 
the 27 Gy group, and 44 [3·2%] in the 26 Gy group; 
table 3), the most common being colorectal cancer 
(25 cases).
287 (7·0%) of 4096 patients died, 151 (3·7%) from breast 
cancer, 125 (3·1%) from other causes, and 11 (0·3%) with 
unknown cause of death and no evidence of disease 
relapse (table 3). Of 27 patients with a cardiac-related death, 
15 had a history of cardiac disease reported at random-
isation or were a current or ex-smoker in the past year.
At least one annual clinical assessment of normal 
tissue effects was available for 3975 (97·0%) of 
4096 patients. At 5 years, any moderate or marked 
clinician-assessed normal tissue effects in the breast or 
chest wall was reported for 98 of 986 (9·9%) 40 Gy 
patients, 155 (15·4%) of 1005 27 Gy patients, and 121 of 
1020 (11·9%) 26 Gy patients (appendix pp 5–6, 8–9), with 
a significant difference between 40 Gy and 27 Gy 
(p=0·0003) but not between 40 Gy and 26 Gy (p=0·17). 
Breast shrinkage was the most prevalent moderate or 
marked effect at 5 years, reported in 50 (5·5%) of 
916 40 Gy patients, 78 (8·2%) of 948 27 Gy patients, and 
65 (6·8%) of 954 26 Gy patients (appendix pp 8–9). 
Longitudinal analysis of all annual clinical assessments 
of normal tissue effects over follow-up showed a 
significantly increased risk of any moderate or marked 
effect in the breast or chest wall for the 27 Gy group 
compared with 40 Gy (OR 1·55 [95% CI 1·32 to 1·83], 
p<0·0001), with no significant difference between 26 Gy 
and 40 Gy (1·12 [0·94 to 1·34], p=0·20; table 4). This 
pattern was similar for the individual effects of breast 
distortion, shrinkage, induration, and breast or chest 
wall oedema, with significantly higher risk for 27 Gy 
than 40 Gy but not for 26 Gy (table 4; appendix pp 5–6). 
Comparing the two five-fraction schedules, 26 Gy had 
significantly lower risk of any moderate or marked 
breast or chest wall normal tissue effects (p=0·0001) and 
breast shrinkage (p=0·0018) compared with 27 Gy. Esti-
mates of 5-year cumulative incidence of any mode rate or 
marked clinician-assessed normal tissue effects in the 
breast or chest wall were 26·8% (95% CI 24·4 to 29·4) 
for 40 Gy, 35·1% (32·4 to 37·9) for 27 Gy, and 28·5% 
(26·0 to 31·1) for 26 Gy (appendix p 10). Results for 
40 Gy in 
15 fractions 
(n=1361)
27 Gy in 
five fractions 
(n=1367)
26 Gy in 
five fractions 
(n=1368)
Local tumour control event (primary 
endpoint)*
31 (2·3%) 27 (2·0%) 21 (1·5%)
Local relapse 23 (1·7%) 22 (1·6%) 17 (1·2%)
Ipsilateral breast, new primary 6 (0·4%) 3 (0·2%) 4 (0·3%)
Cannot differentiate 2 (0·1%) 2 (0·1%) 0
Regional relapse 13 (1·0%) 11 (0·8%) 10 (0·7%)
Distant relapse 59 (4·3%) 69 (5·0%) 76 (5·5%)
Contralateral breast, second primary 23 (1·7%) 20 (1·5%) 23 (1·7%)
Invasive 18 (1·3%) 17 (1·2%) 20 (1·5%)
Ductal carcinoma in situ 5 (0·4%) 3 (0·2%) 2 (0·1%)
Unknown 0 0 1 (0·1%)
Non-breast, second primary 42 (3·1%) 37 (2·7%) 44 (3·2%)
Death 92 (6·8%) 105 (7·7%) 90 (6·6%)
Breast cancer† 47 (3·5%) 51 (3·7%) 53 (3·9%)
Second cancer 12 (0·9%) 16 (1·2%) 10 (0·7%)
Cardiac 10 (0·7%) 9 (0·7%) 8 (0·6%)
Other cause 17 (1·7%) 27 (2·0%) 16 (1·2%)
Unknown 6 (1·2%) 2 (0·1%) 3 (0·2%)
Data are n (%). Patients reporting events of more than one type are included in each relevant row. *Includes angiosarcoma 
in ipsilateral breast (one in the 40 Gy group and two in the 26 Gy group) and six patients with ductal carcinoma in situ 
(three in the 40 Gy group, two in the 27 Gy group, and one in the 26 Gy group). †Includes 13 patients with distant relapse 
before death from other causes (four in the 40 Gy group, four in the 27 Gy group, and five in the 26 Gy group).
Table 3: Relapses, second primary cancers, and deaths by fractionation schedule (n=4096)
Articles
www.thelancet.com   Published online April 28, 2020   https://doi.org/10.1016/S0140-6736(20)30932-6 9
comparison of schedules from the analyses of time to 
first moderate or marked effect were similar to those 
from the long itudinal modelling of all annual clinical 
assessments (appendix p 10).
1796 patients consented to the patient-reported 
outcomes substudy, 18 of whom withdrew consent 
immediately after randomisation or were not given the 
baseline booklet. Questionnaires returned from those 
expected (patients alive and well, not withdrawn) 
were 1771 (99·6%) of 1778 at baseline, 1668 (96·2%) of 
1733 at 3 months, 1622 (94·2%) of 1722 at 6 months, 
1599 (93·7%) of 1707 at 1 year, 1531 (91·7%) of 1669 at 
2 years, and 1334 (84·0%) of 1589 at 5 years. Of the 
1774 patients with at least one completed questionnaire, 
1634 had breast conservation surgery and 140 had 
mastectomy. Change in breast appearance had the 
highest 5-year prevalence, with moderate or marked 
change reported in 140 (32·4%) of 432 for 40 Gy, 
Number of moderate or 
marked events/total 
number of assessments 
over follow-up
Odds ratio for schedule 
(95% CI)
p value for comparison 
with 40 Gy
p value for 
comparison 
between 27 Gy 
and 26 Gy
Odds ratio for years of 
follow-up (95% CI); p value
Any adverse event in the 
breast or chest wall*
·· ·· ·· ·· 0·98 (0·96–1·00); 0·055
40 Gy 651/6121 (10·6%) 1 (ref) ·· ·· ··
27 Gy 1004/6303 (15·9%) 1·55 (1·32–1·83) <0·0001 ·· ··
26 Gy 774/6327 (12·2%) 1·12 (0·94–1·34) 0·20 0·0001 ··
Breast distortion† ·· ·· ·· ·· 0·99 (0·95–1·02); 0·38
40 Gy 232/5724 (4·0%) 1 (ref) ·· ·· ··
27 Gy 363/5953 (6·1%) 1·51 (1·15–1·97) 0·0028 ·· ··
26 Gy 299/5945 (5·0%) 1·20 (0·91–1·60) 0·19 0·083 ··
Breast shrinkage† ·· ·· ·· ·· 1·03 (1·00–1·06); 0·023
40 Gy 330/5728 (5·8%) 1 (ref) ·· ·· ··
27 Gy 503/5944 (8·5%) 1·50 (1·20–1·88) 0·0004 ·· ··
26 Gy 369/5943 (6·2%) 1·05 (0·82–1·33) 0·71 0·0018 ··
Breast induration 
(tumour bed)†
·· ·· ·· ·· 1·00 (0·96–1·04); 0·95
40 Gy 185/5713 (3·2%) 1 (ref) ·· ·· ··
27 Gy 304/5948 (5·1%) 1·56 (1·19–2·05) 0·0013 ·· ··
26 Gy 236/5937 (4·0%) 1·19 (0·90–1·59) 0·23 0·047 ··
Breast induration 
(outside tumour bed)†
·· ·· ·· ·· 0·96 (0·90–1·02); 0·17
40 Gy 45/5712 (0·8%) 1 (ref) ·· ·· ··
27 Gy 137/5943 (2·3%) 2·79 (1·74–4·50) <0·0001 ·· ··
26 Gy 97/5930 (1·6%) 1·90 (1·15–3·14) 0·013 0·059 ··
Telangiectasia ·· ·· ·· ·· 1·21 (1·14–1·29); <0·0001
40 Gy 63/6087 (1·0%) 1 (ref) ·· ·· ··
27 Gy 100/6272 (1·6%) 1·68 (1·07–2·65) 0·025 ·· ··
26 Gy 102/6300 (1·6%) 1·53 (0·96–2·43) 0·070 0·65
Breast or chest wall 
oedema
·· ·· ·· ·· 0·73 (0·69–0·78); <0·0001
40 Gy 89/6097 (1·5%) 1 (ref) ·· ·· ··
27 Gy 217/6287 (3·4%) 2·18 (1·57–3·03) <0·0001 ·· ··
26 Gy 155/6318 (2·4%) 1·47 (1·03–2·09) 0·032 0·0097 ··
Breast or chest wall 
discomfort
·· ·· ·· ·· 0·93 (0·89–0·97); 0·0003
40 Gy 234/6086 (3·8%) 1 (ref) ·· ·· ··
27 Gy 269/6285 (4·3%) 1·10 (0·86–1·40) 0·44 ·· ··
26 Gy 250/6309 (4·0%) 0·98 (0·76–1·26) 0·86 0·35 ··
Results for years of follow-up show trend in normal tissue effects over follow-up across all fractionation schedules. p values are calculated by Wald test; odds ratios are 
estimated from the generalised estimating equations model including all follow-up data and show relative odds of moderate or marked adverse event (vs none or mild) for 
each pairwise comparison of fractionation schedules across all follow-up assessments. *Includes shrinkage, induration, telangiectasia, or oedema. †Patients who had breast 
conservation surgery or mastectomy with reconstruction.
Table 4: Longitudinal analysis of moderate or marked clinician-assessed late normal tissue effects for patients with at least one annual clinical assessment 
(n=3975)
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158 (35·9%) of 440 for 27 Gy, and 136 (31·7%) of 429 for 
26 Gy. 5-year prevalence of patient-reported adverse 
effects were not significantly different between the 
schedules (appendix pp 5–6, 11–12). Patient-reported 
moderate or marked breast hardness or firmness at 
5 years was not significantly increased for 27 Gy 
compared with 40 Gy and breast swelling was not more 
prevalent in both five-fraction schedules than the 40 Gy 
Number of patients 
reporting moderate 
or marked event at 
baseline/total*
Number of moderate or 
marked events/total 
number of assessments 
over 3–60 months of 
follow-up
Odds ratio for 
schedule (95% CI)
p value for 
comparison 
with 40 Gy
p value for 
comparison 
between 
27 Gy and 
26 Gy
Odds ratio for years of 
follow-up (95% CI); 
p value
Protocol-specific items
Breast appearance 
changed
·· ·· ·· ·· ·· 1·03 (1·01–1·05); 
0·0010
40 Gy 170/573 (29·7%) 778/2480 (31·4%) 1 (ref) ·· ·· ··
27 Gy 177/583 (30·4%) 929/2550 (36·4%) 1·22 (1·02–1·46) 0·033 ·· ··
26 Gy 155/581 (26·7%) 770/2563 (30·0%) 0·91 (0·75–1·10) 0·33 0·0018 ··
Breast smaller ·· ·· ·· ·· ·· 1·11 (1·09–1·13); 
<0·0001
40 Gy 96/560 (17·1%) 585/2445 (23·9%) 1 (ref) ·· ·· ··
27 Gy 106/576 (18·4%) 606/2520 (24·0%) 1·05 (0·85–1·29) 0·67 ·· ··
26 Gy 90/574 (15·7%) 515/2542 (20·3%) 0·81 (0·65–1·00) 0·053 0·017 ··
Breast harder or firmer ·· ·· ·· ·· 0·95 (0·93–0·97); 
<0·0001
40 Gy 94/558 (16·8%) 499/2446 (20·4%) 1 (ref) ·· ·· ··
27 Gy 105/572 (18·4%) 690/2512 (27·5%) 1·42 (1·17–1·72) 0·0003 ·· ··
26 Gy 95/566 (16·8%) 626/2534 (24·7%) 1·22 (1·00–1·48) 0·048 0·1007 ··
Skin appearance 
changed
·· ·· ·· ·· ·· 0·96 (0·93–0·99); 
0·0080
40 Gy 78/577 (13·5%) 345/2505 (13·8%) 1 (ref) ·· ·· ··
27 Gy 61/586 (10·4%) 392/2571 (15·2%) 1·03 (0·83–1·28) 0·77 ·· ··
26 Gy 67/580 (11·5%) 338/2576 (13·1%) 0·90 (0·72–1·13) 0·37 0·23 ··
European Organisation for Research and Treatment of Cancer QLQ-BR23 items
Breast pain ·· ·· ·· ·· ·· 0·96 (0·94–0·99); 
0·011
40 Gy 53/583 (9·1%) 338/2538 (13·3%) 1 (ref) ·· ·· ··
27 Gy 42/590 (7·1%) 428/2601 (16·5%) 1·23 (0·98–1·54) 0·068 ·· ··
26 Gy 53/588 (9·0%) 417/2597 (16·1%) 1·23 (0·98–1·53) 0·074 0·96 ··
Breast swollen ·· ·· ·· ·· ·· 0·84 (0·80–0·89); 
<0·0001
40 Gy 56/583 (9·6%) 122/2538 (4·8%) 1 (ref) ·· ·· ··
27 Gy 43/589 (7·3%) 236/2597 (9·1%) 1·46 (1·10–1·94) 0·0080 ·· ··
26 Gy 47/589 (8·0%) 192/2599 (7·4%) 1·27 (0·95–1·69) 0·11 0·22 ··
Breast oversensitive ·· ·· ·· ·· ·· 0·96 (0·93–0·99); 
0·0097
40 Gy 57/579 (9·8%) 283/2528 (11·2%) 1 (ref) ·· ·· ··
27 Gy 42/584 (7·2%) 334/2596 (12·9%) 1·10 (0·87–1·40) 0·43 ·· ··
26 Gy 62/586 (10·6%) 319/2587 (12·3%) 1·11 (0·88–1·41) 0·37 0·91 ··
Skin problems in breast ·· ·· ·· ·· ·· 0·96 (0·92–1·01);  
0·11
40 Gy 26/582 (4·5%) 156/2539 (6·1%) 1 (ref) ·· ·· ··
27 Gy 24/290 (4·1%) 209/2596 (8·0%) 1·25 (0·95–1·65) 0·11 ·· ··
26 Gy 18/590 (3·0%) 164/2592 (6·3%) 0·98 (0·73–1·31) 0·90 0·084 ··
Arm or shoulder pain ·· ·· ·· ·· ·· 1·00 (0·97–1·03);  
>0·99
40 Gy 66/582 (11·3%) 401/2537 (15·8%) 1 (ref) ·· ·· ··
27 Gy 78/591 (13·2%) 441/2601 (17·0%) 1·12 (0·91–1·37) 0·29 ·· ··
26 Gy 81/589 (13·7%) 455/2599 (17·5%) 1·14 (0·93–1·40) 0·2006 0·83 ··
(Table 5 continues on next page)
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schedule, at the prespecified cutoff of p=0·005. 
Longitudinal analyses of all patient assessments from 
baseline to 5 years showed a significantly higher risk of 
moderate or marked breast hardness or firmness for 
27 Gy compared with 40 Gy (OR 1·42, 1·17, 1·72, 
p=0·0003), and a lower risk of change in breast 
appearance for 26 Gy compared with 27 Gy (p=0·0018), 
but no significant differences between schedules for the 
other normal tissue effects (table 5; appendix pp 5–6).
Of the 1737 patients who consented to the photographic 
substudy, baseline photographs were received for 
1634 (94·1%), and 2-year or 5-year photo graphs were 
available for 1385 (79·7%). 1309 (75·4%) were patients who 
had breast conservation surgery; for these patients, 2-year 
photographs were assessed in 1267 and 5-year photographs 
were assessed in 875 (appendix p 13). 226 patients died or 
withdrew from the photographic substudy by year 5; for 
the remainder, the most common reasons for photographs 
not being taken were appointments not made because 
of clerical errors at the centres, patients not attending 
clinic visits, and patients withdrawing consent from the 
substudy. At 2 years, mild or marked change in photo-
graphic breast appearance was reported in 35 (8·5%) of 
411 for 40 Gy, 67 (15·6%) of 429 for 27 Gy, and 46 (10·8%) of 
427 for 26 Gy; corresponding results at 5 years were 
34 (12·0%) of 283 for 40 Gy, 83 (26·9%) of 308 for 27 Gy, 
and 37 (13·0%) of 284 for 26 Gy (appendix p 13). Modelling 
2-year and 5-year photographic assessments together, 
27 Gy had a significantly increased risk of mild or marked 
change in breast appearance compared with 40 Gy 
(OR 2·29 [95% CI 1·60 to 3·27], p<0·0001), with no 
significant difference between 26 Gy and 40 Gy (OR 1·26 
[0·85 to 1·86], p=0·24; appendix p 13). 26 Gy had a 
significantly lower risk of change in photographic breast 
appearance than 27 Gy (p=0·0006).
The unadjusted α/β estimate for any moderate or 
marked clinician-assessed normal tissue effects in the 
breast or chest wall was 1·7 Gy (95% CI 1·2 to 2·3), 
giving EQD2 estimates of 47·1 Gy for 40 Gy in 15 frac tions, 
51·6 Gy for 27 Gy in 5 fractions, and 48·3 Gy for 26 Gy 
in 5 fractions; adjusting for prognostic factors (age, 
boost, and whole-breast planning treatment volume as 
a proxy for breast size) made very little difference. 
The α/β estimated from the photographic endpoint 
(adjusting for breast size and surgical deficit assessed 
from the baseline photographs) was very similar (1·8 Gy 
[1·1 to 2·4]). The unadjusted α/β estimate for patient-
reported change in breast appearance was 2·3 Gy 
(1·8 to 2·9), resulting in EQD2 estimates of 46·1 Gy for 
40 Gy, 48·2 Gy for 27 Gy, and 45·2 Gy for 26 Gy; adjusting 
for covariates made minimal difference.
The most common specialist referral for radiotherapy-
related adverse effects during follow-up was to lympho-
edema clinics (appendix p 14). Incidence of ischaemic 
heart disease, symptomatic rib fracture, and symptomatic 
lung fibrosis was very low at this stage of follow-up 
(appendix p 14).
Discussion
We demonstrated non-inferiority, measured in terms of 
ipsilateral breast tumour relapse, of 27 Gy and 26 Gy five-
fraction schedules compared with 40 Gy in 15 fractions at 
5 years’ follow-up for patients with early breast cancer, 
most of whom were treated by local tumour excision and 
sentinel node biopsy for node-negative disease. Normal 
tissue effects up to 5 years for the 26 Gy in five fractions 
schedule were similar to those with the 40 Gy in 
15 fractions schedule. Low rates of ipsilateral breast 
tumour relapse and of moderate or marked late normal 
tissue effects can be attributed to improvements in all 
Number of patients 
reporting moderate 
or marked event at 
baseline/total*
Number of moderate or 
marked events/total 
number of assessments 
over 3–60 months 
follow-up
Odds ratio for 
schedule (95% CI)
p value for 
comparison 
with 40 Gy
p value for 
comparison 
between 
27 Gy and 
26 Gy
Odds ratio for years of 
follow-up (95% CI); 
p value
(Continued from previous page)
Arm or hand swollen ·· ·· ·· ·· ·· 1·06 (1·00–1·11);  
0·031
40 Gy 24/582 (4·1%) 101/2536 (4·0%) 1 (ref) ·· ·· ··
27 Gy 17/588 (2·9%) 103/2600 (4·0%) 0·95 (0·66–1·36) 0·77 ·· ··
26 Gy 22/590 (3·7%) 124/2592 (4·8%) 1·14 (0·80–1·62) 0·46 0·31 ··
Difficulty raising arm ·· ·· ·· ·· ·· 1·04 (0·99–1·08); 
0·089
40 Gy 27/582 (4·6%) 171/2533 (6·7%) 1 (ref) ·· ·· ··
27 Gy 36/589 (6·1%) 209/2599 (8·0%) 1·24 (0·94–1·63) 0·12 ·· ··
26 Gy 37/587 (6·3%) 188/2596 (7·2%) 1·12 (0·85–1·48) 0·42 0·46 ··
Results for years of follow-up show trend in normal tissue effects over follow-up across all fractionation schedules. p values are calculated by Wald test; odds ratios are 
estimated from the generalised estimating equations model including all questionnaires (baseline to 5 years) and show relative odds of moderate or marked adverse events 
(vs none or mild) for each pairwise comparison of fractionation schedules across all questionnaires. *Total is those who completed the corresponding question.
Table 5: Longitudinal analysis of moderate or marked patient-assessed late normal tissue effects from baseline to 5 years for patients with at least one 
completed questionnaire (n=1774)
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diagnostic and treat ment modalities and to the com-
mitment of patients to early diagnosis and randomised 
trials.20
The 10-year analyses of ipsilateral breast tumour 
relapse and normal tissue effects reported by earlier 
Canadian5 and UK trials3,4,6–8 confirm that although 
normal tissue effects continue to accumulate beyond 
5 years, there is evidence that relative differences between 
test and control groups change very little over time.21 In 
the START-B trial, the HR for clinician-assessed breast 
shrinkage after 40 Gy in 15 fractions compared with 
50 Gy in 25 fractions was 0·83 (95% CI 0·66–1·04) at 
5 years and 0·80 (0·67–0·96) at 10 years, by which 
time the proportion of patients with breast shrinkage 
increased from 11·4% (9·5–13·6) at 5 years to 26·2% 
(23·2–29·6) at 10 years.8 The findings of FAST-Forward 
can be applied to different prognostic groups in view of 
the very low overall ipsilateral breast tumour relapse 
incidence, a conclusion consistent with a meta-analysis 
of the 5861 patients entered into the three START trials, 
which identified no inconsistency of effect in terms of 
normal tissue effects or recurrence risk across any of the 
prognostic or treatment subgroups investigated.8
The absence of a detectable dose response for local 
tumour control between 26 Gy and 27 Gy in five frac-
tions is a potential limit to precision, but this feature 
reflects the shallowness of the dose response curve for 
subclinical breast cancer that is around the 98% local 
tumour control level, so the –0·4% estimated difference 
in absolute levels of ipsilateral breast tumour relapse 
between 27 Gy and 26 Gy probably reflects random 
sampling variability in the ipsilateral breast tumour 
relapse rate or chance imbalances in unmeasured 
prognostic factors between test groups. For late normal 
tissue effects, the dose response is much steeper, 
enabling detection of clinically and statistically signifi-
cant differ ences in event rates between 26 Gy and 27 Gy 
in five fractions. The five-fraction schedule isoeffective 
with 40 Gy in 15 fractions allows direct estimation of 
α/β for late normal tissue effects, which is consistent 
with values generated from our other trials. The 
α/β value of 3·7 Gy (95% CI 0·3–7·1) for tumour control 
in FAST-Forward is similar to the 3·5 Gy (1·2–5·7) 
estimated from the START pilot and START-A trials.8 
Point estimates of α/β values, assuming no effect of 
time, for late normal tissue effects in FAST-Forward 
scored by clinicians, patients, and photographic assess-
ments are closer to 2 Gy than the 3 Gy estimated in the 
earlier START8 and FAST trials,14 but 95% CIs overlap 
for each endpoint in all trials. In FAST, 915 women were 
randomly assigned after breast conservation surgery for 
node negative disease to 50 Gy in 25 fractions versus 
two dose levels of a five-fraction regimen delivered once 
weekly, thereby ensuring complete repair between 
fractions and controlling for overall treatment time.13,14 
The α/β value for change in photographic breast 
appearance in FAST was 2·6 Gy (1·4–3·7). Uncertainty 
about biological processes, which include a time factor 
in FAST-Forward, does not interfere with clinical evalu-
ation and decisions on implementation of FAST-Forward 
results in similar patient groups.
The five-fraction regimen is relevant to partial-breast 
radiotherapy, the preferred alternative to whole-breast 
radiotherapy for many women after recent phase 3 
trials.22–25 Beyond its safety and effectiveness, the 26 Gy 
FAST-Forward schedule is convenient and substantially 
less expensive for patients and for health services. It is 
also likely to be safe for patients requiring regional radio-
therapy, an approach that is under formal assessment in 
a randomised FAST-Forward substudy comparing 40 Gy 
in 15 fractions and 26 Gy in five fractions. Assuming no 
effect of time, 26 Gy in five fractions is equivalent to 
46·8 Gy and 53·7 Gy in 2-Gy fractions assuming 
α/β values of 2 Gy and 1 Gy, respectively, dose intensities 
well within the limits of tolerance for these structures.26,27 
In terms of limitations of our study, there is no reason to 
consider the heart more sensitive to fraction size than 
most other soft tissues. It is undoubtedly sensitive to 
total dose but the tiny number of cardiac events in FAST-
Forward prevents meaningful analysis.28 Any heart 
exposure is potentially harmful even after 2 Gy fractions, 
so the priority is to exclude the heart from the treatment 
volume as far as possible using deep inspiration breath 
hold or a similar technique,29,30 or partial breast 
radiotherapy.23 The size of the trial prevents reliable 
subgroup analyses by patient age, tumour grade, receptor 
status, and systemic therapies, but consistent with our 
10-year analyses of almost 6000 patients in the START 
hypofractionation trials, there is no suggestion of 
heterogeneity.8 Finally, synchronous boost regimens 
were avoided despite current interest in this application 
of hypofractionation. It is safer to consider boost as an 
independent treatment variable such as tumour grade or 
adjuvant systemic therapy whose impacts are randomly 
distributed across treatment groups. This allows a pure 
assessment of whole-breast hypofractionation without 
having to con sider the partial volume effects of different 
breast dose levels. Routine implementation of 26 Gy in 
five fractions can more naturally incorporate appropriate 
five-fraction synchronous boost regimens.
In conclusion, 5-year ipsilateral breast tumour relapse 
incidence after a 1-week course of adjuvant breast 
radiotherapy delivered in five fractions is non-inferior to 
the standard 3-week schedule according to the predefined 
inferiority threshold. The 26 Gy dose level is similar to 
40 Gy in 15 fractions in terms of patient-assessed normal 
tissue effects, clinician-assessed normal tissue effects, 
and photographic change in breast appearance, and is 
similar to normal tissue effects expected after 46–48 Gy in 
2 Gy fractions. The consistency of FAST-Forward results 
with earlier hypofractionation trials supports the adoption 
of 26 Gy in five daily fractions as a new standard for 
women with operable breast cancer requiring adjuvant 
radiotherapy to partial or whole breast.
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